PrabotulinumtoxinA injections found to significantly reduce the pain and Neck Disability Index scores among patients with shoulder girdle and cervical myofascial pain syndrome, as per research carried out at The Catholic University of Korea. Myofascial pain syndrome is a well-known painful infirmity. Prior studies assessing the effectiveness of botulinum toxin for the myofascial pain syndrome treatment are inadequate, with variable outcomes. Therefore, this prospective study was conducted to examine the efficacy and safety of direct injection of Prabotulinumtoxin A into painful muscle groups for shoulder girdle and cervical myofascial pain syndrome. A total of 12 patients with shoulder and neck pain were administered with PrabotulinumtoxinA injection. In the mid belly, painful muscles holding trigger points were injected. The tolerability, pain intensity, quality of life and safety were measured at baseline, 6 and 12 weeks after the treatment. 

At 12 weeks, PrabotulinumtoxinA exhibited a considerable reduction in pain intensity. As compared to baseline, 41.7% patients responded well to PrabotulinumtoxinA and experienced 30% reduction in pain at six weeks. However, patients exhibited considerable improvement in the Neck Disability Index scores both at 6 and 12 weeks after the treatment. The study observed no adverse events. At 12 weeks, a significant improvement in health related quality of life and pain scores was noted with prabotulinumtoxinA injection into persistent painful muscles connected with shoulder girdle and cervical myofascial pain syndrome. Injections showed significant tolerability. On the basis of these findings, PrabotulinumtoxinA could be an effective approach to manage myofascial pain syndrome; however, these are the preliminary findings, more investigation should carefully examine using randomized, controlled, prospective trials.